EUCTR2004-004980-30-IS进行中（未招募）1 期
A single-site, open-label, randomised dose finding study to examine safety, tolerability and dose-related effects of DG-031 on inflammatory biomarkers in serum of FLAP and/or LTA4 hydrolase haplotype positive patients with coronary artery disease. - N/A
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The criteria listed below will be assessed at Visit 1 unless stated otherwise. Laboratory measurements to be performed require an overnight fast =8 hours in duration.
- •1.Age 40 to 75.
- •2.Carrier of the FLAP and/or the LTA4 hydrolase haplotype (as suggested by results of previous deCODE genetics’ studies).
- •3.Diagnosis of CAD (based on interview, medication history and physical examination).
- •4.All women of childbearing potential must have a negative urine pregnancy test at Visit 1. Since the interaction of DG-031 with hormonal contraceptives has not been fully established, it must be considered to potentially decrease their efficacy. Therefore, all women of childbearing potential are required to use 2 adequate barrier methods of contraception throughout the study starting with Visit 1 and for 14 days after the last dose of study medication. Adequate barrier methods of contraception are defined as use of 2 of the following: diaphragm, condom (by the partner), hormonal or copper intrauterine device, or spermicide. Only women agreeable to reliably using double-barrier methods of contraception should be enroled.
- •Note: Women of childbearing potential are defined as premenopausal and have not had surgical sterilisation (hysterectomy or bilateral tubal ligation or bilateral oophorectomy). Postmenopausal status is defined as age 43 years and (1) no menses for >1 year but <3 years and confirmed by FSH levels elevated into the postmenopausal range or (2) no menses for at least 3 years.
- •5.Understanding of the study procedures and agreement to participate in the study by giving written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Individuals are excluded from participation in the study if they meet any of the following criteria at Visit 1.
- •1.Congestive heart failure (CHF).
- •2.Any experimental treatment within 2 months of screening or planned for the following 3 months.
- •3.Acute CV event (such as ACS, MI or stroke) within 1 month prior to enrolment.
- •4.Elevated CPK above 3 fold upper normal limit (UNL). Other liver function tests and kidney function tests above 1.5 fold upper normal limit.
- •5.Immunocompromised subjects, including subjects known to be HIV positive or with malignant disease and/or on chronic immunosuppressive therapy.
- •6.Subjects known to have positive serology results for HBsAg, HCV Ab.
- •7.Treatment with immunosuppressive cytotoxic drugs or corticosteroids within 6 weeks or during conduct of study.
- •8.Major surgery within 6 weeks prior to enrolment.
- •9.Any other major intercurrent illness and other condition, which, in the investigator’s judgement, will interfere with the subject’s participation in this study.
- •10.Subjects not willing to return for follow-up or with known history of non-compliance.
- •11.Subjects not willing to adhere to restrictions of alcohol use for the duration of the study (=3 units of alcohol/day or =15 units of alcohol/week and no alcohol for 48 hours prior to clinic visits).
- •Note: A unit of alcohol is defined as a single measure of spirit (25 ml), one small glass of sherry or fortified spirit (50 ml), one small glass of wine (125 ml) or one small regular strength beer (330 ml, 4-5%).
- •12.Pregnant or lactating women.
- •13.Poor mental function or any other reason to expect difficulty in complying with the requirements of the study.
研究者
相似试验
进行中（未招募）
不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapyAnemic patients undergoing chemotherapyEUCTR2005-005405-37-EEF. Hoffmann-La Roche Ltd.200
进行中（未招募）
不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapyAnemic patients undergoing chemotherapyEUCTR2005-005405-37-BEF. Hoffmann-La Roche Ltd.200
进行中（未招募）
不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV nonsmall cell lung cancer receiving first line myelosuppressive chemotherapy - NDAnemia in cancer patients receiving chemotherapyMedDRA version: 6.1Level: PTClassification code 10061873EUCTR2005-005405-37-ITROCHE200
进行中（未招募）
不适用
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapyAnemic patients undergoing chemotherapyEUCTR2005-005405-37-FIF. Hoffmann-La Roche Ltd.200
进行中（未招募）
1 期
A multicenter, randomized, open-label dose finding study of RO0503821 in anemic patients with stage IIIB or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapyEUCTR2005-005405-37-CZF. Hoffmann-La Roche Ltd.200